Argos Therapeutics, Inc.
ARGS
ARGS was delisted on the 24th of April, 2018.
26 hedge funds and large institutions have $39.1M invested in Argos Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
1% more capital invested
Capital invested by funds: $38.8M → $39.1M (+$327K)
0% more funds holding
Funds holding: 26 → 26 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$2.67M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$374K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$360K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$191K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Caisse de Depot et Placement du Quebec (CDPQ)
Montreal,
Quebec, Canada
|
-$2.82M |
| 2 |
SKK
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
-$228K |
| 3 |
AGA
Altrinsic Global Advisors
Stamford,
Connecticut
|
-$121K |
| 4 |
KeyBank National Association
Cleveland,
Ohio
|
-$38.8K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$20K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AIG
26
American International Group
New York
| $660 | -$1.26K | -7 | -70% |
|
|
SKK
27
Shepherd Kaplan Krochuk
Boston,
Massachusetts
| – | -$228K | -1,135 | Closed |
|
|
28
Bank of America
Charlotte,
North Carolina
| – | -$20K | -100 | Closed |
|
29
BNP Paribas Financial Markets
Paris,
France
| – | -$3.67K | -18 | Closed |
|
30
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
| – | -$3 | -13 | Closed |
|
31
Barclays
London,
United Kingdom
| – | -$1K | -3 | Closed |
|
ARGS Hedge Fund Activity: Q4 2014 in Review
26 of the 3,751 institutional investors tracked by Wall St. Rank reported a position in Argos Therapeutics, Inc. (ARGS) for Q4 2014, worth a combined $39.1M — up 0.84% from $38.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ARGS positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Wasatch Advisors, adding an estimated $2.67M. The largest seller was Caisse de Depot et Placement du Quebec (CDPQ), cutting an estimated $2.82M.
- 26 institutional investors held Argos Therapeutics, Inc. (ARGS) as of Q4 2014, unchanged from Q3 2014.
- Funds reported $39.1M of Argos Therapeutics, Inc. stock for Q4 2014, up 0.84% quarter-over-quarter.
- 6 funds opened new Argos Therapeutics, Inc. positions in Q4 2014 and 5 closed out, a net change of +1 holder.
- The largest Argos Therapeutics, Inc. buyer in Q4 2014 was Wasatch Advisors, an estimated $2.67M added.
- The largest Argos Therapeutics, Inc. seller in Q4 2014 was Caisse de Depot et Placement du Quebec (CDPQ), an estimated $2.82M sold.
Based on aggregated 13F filings for Q4 2014.